Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma

  • HEAD AND NECK: Human Papilloma Virus Associated Head and Neck Squamous Cell Carcinoma (WK Mydlarz and C Fakhry, Section Editors)
  • Published:
Current Otorhinolaryngology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of this study is to review the treatment options for recurrent and metastatic human papillomavirus-associated oropharyngeal squamous cell carcinoma (R/M HPV + OPSCC).

Recent Findings

Researchers are currently investigating novel biomarkers to predict response to immunotherapy as well as innovative treatments to improve patient outcomes, such as tumor vaccines and T-cell therapies.

Summary

While some patients with R/M HPV + OPSCC may benefit from surgery and/or radiation, many individuals require systemic therapies, including cytotoxic chemotherapy, molecular targeted agents, and immune checkpoint inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014;32(30):3365–73.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110(3 Pt 2 Suppl 93):1–18.

  4. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008;26(34):5518–23.

    Article  CAS  PubMed  Google Scholar 

  5. Sweeny L, Rosenthal EL, Clemons L, Stevens TM, Cook McIntosh ER, Carroll WR. Outcomes after surgical salvage for recurrent oropharyngeal squamous cell carcinoma. Oral Oncol. 2016;60:118–24.

    Article  PubMed  Google Scholar 

  6. Galloway TJ, Zhang QE, Nguyen-Tan PF, et al. Prognostic value of p16 status on the development of a complete response in involved oropharynx cancer neck nodes after cisplatin-based chemoradiation: a secondary analysis of nrg oncology rtog 0129. Int J Radiat Oncol Biol Phys. 2016;96(2):362–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Patel SN, Cohen MA, Givi B, et al. Salvage surgery for locally recurrent oropharyngeal cancer. Head Neck. 2016;38(Suppl 1):E658-664.

    Article  PubMed  Google Scholar 

  8. Joseph AW, Guo T, Hur K, et al. Disease-free survival after salvage therapy for recurrent oropharyngeal squamous cell carcinoma. Head Neck. 2016;38(Suppl 1):E1501-1509.

    Article  PubMed  Google Scholar 

  9. Ionna F, Bossi P, Guida A, et al. Recurrent/metastatic squamous cell carcinoma of the head and neck: a big and intriguing challenge which may be resolved by integrated treatments combining locoregional and systemic therapies. Cancers (Basel). 2021;13(10):2371.

    Article  CAS  Google Scholar 

  10. Shaikh H, Karivedu V, Wise-Draper TM. Managing recurrent metastatic head and neck cancer. Hematol Oncol Clin North Am. 2021;35(5):1009–20.

    Article  PubMed  Google Scholar 

  11. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. O’Sullivan B, Huang SH, Perez-Ordonez B, et al. Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol. 2012;103(1):49–56.

    Article  PubMed  Google Scholar 

  13. Trosman SJ, Koyfman SA, Ward MC, et al. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol Head Neck Surg. 2015;141(5):457–62.

    Article  PubMed  Google Scholar 

  14. Sacks R, Law JY, Zhu H, et al. Unique patterns of distant metastases in hpv-positive head and neck cancer. Oncology. 2020;98(3):179–85.

    Article  PubMed  Google Scholar 

  15. Miles BA. Treatment of human papillomavirus associated oropharyngeal cancer. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on 05 Dec 2021).

  16. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.

    Article  CAS  PubMed  Google Scholar 

  17. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67.

    Article  CAS  PubMed  Google Scholar 

  19. Hsieh RW, Borson S, Tsagianni A, Zandberg DP. Immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck. Front Oncol. 2021;11:705614.

  20. Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110(3 Pt 2 Suppl 93):1–18.

  21. Bulbul MG, Genovese TJ, Hagan K, Rege S, Qureshi A, Varvares MA. Salvage surgery for recurrent squamous cell carcinoma of the head and neck: systematic review and meta-analysis. Head Neck. Published online November 3, 2021.

  22. Wong LY, Wei WI, Lam LK, Yuen APW. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25(11):953–9.

    Article  PubMed  Google Scholar 

  23. Agra IMG, Carvalho AL, Pontes E, et al. Postoperative complications after en bloc salvage surgery for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2003;129(12):1317–21.

    Article  PubMed  Google Scholar 

  24. Kostrzewa JP, Lancaster WP, Iseli TA, Desmond RA, Carroll WR, Rosenthal EL. Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope. 2010;120(2):267–72.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lee SC, Shores CG, Weissler MC. Salvage surgery after failed primary concomitant chemoradiation. Curr Opin Otolaryngol Head Neck Surg. 2008;16(2):135–40.

    Article  PubMed  Google Scholar 

  26. Kim AJ, Suh JD, Sercarz JA, et al. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. Laryngoscope. 2007;117(6):1019–23.

    Article  PubMed  Google Scholar 

  27. White H, Ford S, Bush B, et al. Salvage surgery for recurrent cancers of the oropharynx: comparing TORS with standard open surgical approaches. JAMA Otolaryngol Head Neck Surg. 2013;139(8):773–8.

    Article  PubMed  Google Scholar 

  28. Grant DG, Salassa JR, Hinni ML, Pearson BW, Hayden RE, Perry WC. Transoral laser microsurgery for recurrent laryngeal and pharyngeal cancer. Otolaryngol Head Neck Surg. 2008;138(5):606–13.

    Article  PubMed  Google Scholar 

  29. Dagan R, Morris CG, Kirwan JM, et al. Elective neck dissection during salvage surgery for locally recurrent head and neck squamous cell carcinoma after radiotherapy with elective nodal irradiation. Laryngoscope. 2010;120(5):945–52.

    PubMed  Google Scholar 

  30. Temam S, Koka V, Mamelle G, et al. Treatment of the N0 neck during salvage surgery after radiotherapy of head and neck squamous cell carcinoma. Head Neck. 2005;27(8):653–8.

    Article  PubMed  Google Scholar 

  31. Farrag TY, Lin FR, Cummings CW, et al. Neck management in patients undergoing postradiotherapy salvage laryngeal surgery for recurrent/persistent laryngeal cancer. Laryngoscope. 2006;116(10):1864–6.

    Article  PubMed  Google Scholar 

  32. Ganly I, Patel SG, Matsuo J, et al. Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg. 2006;132(1):59–66.

    Article  PubMed  Google Scholar 

  33. Florescu C, Thariat J. Local ablative treatments of oligometastases from head and neck carcinomas. Crit Rev Oncol Hematol. 2014;91(1):47–63.

    Article  CAS  PubMed  Google Scholar 

  34. Su W, Liu J, Miles BA, et al. Adjuvant radiation therapy alone for hpv related oropharyngeal cancers with high risk features. PLoS One. 2016;11(12):e0168061.

  35. Salama JK, Vokes EE. Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol. 2008;35(3):251–61.

    Article  CAS  PubMed  Google Scholar 

  36. Patel PR, Salama JK. Reirradiation for recurrent head and neck cancer. Expert Rev Anticancer Ther. 2012;12(9):1177–89.

    Article  CAS  PubMed  Google Scholar 

  37. McDonald MW, Lawson J, Garg MK, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys. 2011;80(5):1292–8.

    Article  PubMed  Google Scholar 

  38. Romesser PB, Cahlon O, Scher ED, et al. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys. 2016;95(1):386–95.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Baliga S, Kabarriti R, Ohri N, et al. Stereotactic body radiotherapy for recurrent head and neck cancer: a critical review. Head Neck. 2017;39(3):595–601.

    Article  PubMed  Google Scholar 

  40. Sutera P, Clump DA, Kalash R, et al. Initial results of a multicenter phase 2 trial of stereotactic ablative radiation therapy for oligometastatic cancer. Int J Radiat Oncol Biol Phys. 2019;103(1):116–22.

    Article  PubMed  Google Scholar 

  41. Vermorken JB. Medical treatment in head and neck cancer. Ann Oncol. 2005;16 Suppl 2:ii258–264.

  42. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5568–77.

    Article  CAS  PubMed  Google Scholar 

  43. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578–87.

    Article  CAS  PubMed  Google Scholar 

  44. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–7.

    Article  CAS  PubMed  Google Scholar 

  45. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646–8654.

  46. • Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014–01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463–75. This clinical trial demonstrated that the TPEx regimen had similar OS outcomes to the EXTREME regimen, but a better safety profile and easier administration logistics, offering an alternative frontline treatment for R/M disease, especially in patients who are ineligible for immunotherapy.

    Article  CAS  PubMed  Google Scholar 

  47. Machiels JPH, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (Lux-head & neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(5):583–94.

    Article  CAS  PubMed  Google Scholar 

  48. Ho AL, Brana I, Haddad R, et al. Tipifarnib in head and neck squamous cell carcinoma with hras mutations. J Clin Oncol. 2021;39(17):1856–64.

    Article  CAS  PubMed  Google Scholar 

  49. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.

    Article  CAS  PubMed  Google Scholar 

  50. Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119(2):153–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. León X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol). 2005;17(6):418–24.

    Article  Google Scholar 

  52. Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase ii study. J Clin Oncol. 2017;35(14):1542–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67.

    Article  CAS  PubMed  Google Scholar 

  54. Gillison ML, Blumenschein G, Fayette J, et al. Checkmate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer. Oncologist. 2018;23(9):1079–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. •• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–28. This landmark clinical trial demonstrated the OS benefits of pembrolizumab monotherapy as well as in combination with chemotherapy in the frontline R/M setting, leading to approval for this indication in 2019 and fundamentally changing the treatment algorithm for R/M disease.

    Article  CAS  PubMed  Google Scholar 

  56. Guigay J, Fayette J, Mesia R, et al. TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(15_suppl):6002.

  57. Trivedi S, Sun L, Aggarwal C. Immunotherapy for head and neck cancer. Hematol Oncol Clin North Am. 2021;35(5):1021–37.

    Article  PubMed  Google Scholar 

  58. Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142–52.

    Article  CAS  PubMed  Google Scholar 

  59. Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Siu LL, Even C, Mesía R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with pd-l1-low/negative recurrent or metastatic hnscc: the phase 2 condor randomized clinical trial. JAMA Oncol. 2019;5(2):195–203.

    Article  PubMed  Google Scholar 

  61. Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942–50.

    Article  CAS  PubMed  Google Scholar 

  62. Le X, Ferrarotto R, Wise-Draper T, Gillison M. Evolving role of immunotherapy in recurrent metastatic head and neck cancer. J Natl Compr Canc Netw. 2020;18(7):899–906.

    Article  CAS  PubMed  Google Scholar 

  63. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Seiwert TY, Haddad R, Bauml J, et al. Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC). In: Abstract LB-339 presented at: American Association for Cancer Research Annual Meeting. Chicago. 2018.

  66. Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593.

  67. Li W, Wildsmith S, Ye J, et al. Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: durvalumab (D) tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure. J Clin Oncol. 2020;38:6511.

    Article  Google Scholar 

  68. Wang J, Sun H, Zeng Q, et al. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep. 2019;9(1):13404.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (Hnscc). J Immunother Cancer. 2019;7(1):184.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Zandberg DP, Velez M, Menk AV, et al. The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M). J Clin Oncol. 2020;38(15_suppl):6546–6. https://doi.org/10.1200/JCO.2020.38.15_suppl.6546

  71. Oliva M, Spreafico A, Taberna M, et al. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol. 2019;30(1):57–67.

    Article  CAS  PubMed  Google Scholar 

  72. Ferris RL, Blumenschein GR Jr, Harrington K, et al. Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: analyses from CheckMate 141. Proc Am Assoc Cancer Res. Ann Meet. 2017;77. Abstract nr CT022 2017. Washington, DC Philadelphia (PA: AACR; Cancer Res).

  73. Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101(6):412–23.

    Article  CAS  PubMed  Google Scholar 

  74. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012;4(155):155ra138.

  75. Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother. 2016;12(6):1418–1429.

  76. Schuler PJ, Harasymczuk M, Visus C, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014;20(9):2433–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(1):67–73.

    Article  PubMed  Google Scholar 

  78. Sacco JJ, Evans M, Harrington KJ, et al. Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001. Hum Vaccin Immunother. 2016;12(4):1085–6.

    Article  PubMed  Google Scholar 

  79. Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral t cell infiltration and improves anti-pd-1 immunotherapy. Cell. 2017;170(6):1109-1119.e10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Zacharakis N, Chinnasamy H, Black M, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Stevanović S, Helman SR, Wunderlich JR, et al. A phase ii study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin Cancer Res. 2019;25(5):1486–93.

    Article  PubMed  Google Scholar 

  84. Lamers CHJ, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20-22.

    Article  PubMed  Google Scholar 

  85. Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Draper LM, Kwong MLM, Gros A, et al. Targeting of hpv-16+ epithelial cancer cells by tcr gene engineered t cells directed against e6. Clin Cancer Res. 2015;21(19):4431–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Jin BY, Campbell TE, Draper LM, et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018;3(8):99488.

    Article  PubMed  Google Scholar 

  88. Doran SL, Stevanović S, Adhikary S, et al. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase i/ii study. J Clin Oncol. 2019;37(30):2759–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Norberg S, Nagarsheth N, Sinkoe A, et al. Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers. JCO. 2020;38(15_suppl):101–101.

  90. Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450–62.

    Article  CAS  PubMed  Google Scholar 

  91. Bourhis, J et al. Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial. ESMO Virtual Congress 2021. LBA35.

  92. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor hpv dna for the surveillance of cancer recurrence in hpv-associated oropharyngeal cancer. J Clin Oncol. 2020;38(10):1050–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Hanna G, Posner M, Genden E, et al. Detection of occult recurrence using circulating HPV tumor DNA among patients treated for HPV-driven oropharyngeal squamous cell carcinoma. In: Abstract 3: Presented at 2022 Multidisciplinary Head and Neck Cancers Symposium. Phoenix, Arizona.

  94. Chera BS, Kumar S, Beaty BT, et al. Rapid clearance profile of plasma circulating tumor hpv type 16 dna during chemoradiotherapy correlates with disease control in hpv-associated oropharyngeal cancer. Clin Cancer Res. 2019;25(15):4682–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

    Michael Wotman & Lindsey Draper

  2. Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

    Brandon Gold

  3. Department of Internal Medicine, Icahn School of Medicine at Mount Sinai Beth Israel, New York City, NY, USA

    Mai Takahashi

  4. Department of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

    Marshall Posner

Authors
  1. Michael Wotman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brandon Gold
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mai Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lindsey Draper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marshall Posner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Wotman.

Ethics declarations

Conflict of Interest

Dr. Posner reports that he is DMC chair for Merck Pembro head and neck trials and advisory boards for Hookipa, Naveris, Coherus, this year 1 meeting each. The other authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on HEAD AND NECK: Human Papilloma Virus Associated Head and Neck Squamous Cell Carcinoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wotman, M., Gold, B., Takahashi, M. et al. Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma. Curr Otorhinolaryngol Rep 10, 208–217 (2022). https://doi.org/10.1007/s40136-022-00402-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40136-022-00402-9

Keywords

Search

Navigation